India Pharma Outlook Team | Tuesday, 14 July 2026
Emcure has tightened its grip on Gennova with a Rs 231.8 crore acquisition. The deal will make Gennova a wholly owned subsidiary of the company.
Emcure will buy the remaining 12.05 percent stake through an all-cash transaction. The move supports the company's One Emcure strategy.
It also aims to simplify operations and strengthen its biologics business. The acquisition comes with a leadership change and a planned separation of Gennova's mRNA business.
Emcure Pharmaceuticals will acquire the remaining 12.05 percent stake in Gennova Biopharmaceuticals for Rs 231.8 crore. The company disclosed the deal in a regulatory filing.
The stake is currently held by outgoing CEO Dr. Sanjay Singh and other minority shareholders. Once the transaction closes, Gennova will become a 100 percent owned subsidiaryy of Emcure.
The acquisition will be completed through an all-cash payment.
Also Read: Pharmaceutical 4.0: Redefines Compliance, Automation & AI
Dr. Sanjay Singh will step down as Gennova's CEO after the transaction. Samit Mehta, Whole-Time Director at Emcure, will take charge of the company.
The mRNA business will no longer remain with Gennova. It will move to ImmunoScript Life Sciences, a company founded by Dr. Singh.
The transfer follows a business transfer agreement signed earlier between the companies. Gennova will continue to focus on biologics and biosimilars after the restructuring.
Emcure said the changes are part of its One Emcure strategy. The company wants a simpler corporate structure and better operational focus.
"As part of the One Emcure framework, Gennova will continue to anchor the Group's biologics and biosimilars capabilities. Our work will complement Emcure's broader R&D and pipeline priorities, with a focus on execution, quality and disciplined development across our chosen therapy areas," said Samit Mehta, Whole Time Director and CEO, Gennova Biopharmaceuticals.
Emcure said the transaction will not have a material impact on its consolidated financial performance. The company also expects no change in its debt reduction plans.
Its capital expenditure and research and development investments will continue as planned.
Gennova was established in 2001 and became Gennova Biopharmaceuticals in 2006. The company has developed a portfolio of biologics and biosimilars.
Its marketed products include Elaxim, Vintor, Xgrast, and Hamsyl.
For FY26, Gennova reported revenue of Rs 491 crore. The company posted a net profit of Rs 5.43 crore.
With full ownership, Emcure will have complete control over Gennova's future operations. The company also expects better alignment across its biologics business while the mRNA platform continues independently under ImmunoScript Life Sciences.
